Sie suchten nach: the keele start back screening tool (Englisch - Griechisch)

the rate of false positive samples should be low enough to make the use of a screening tool advantageous.
Το ποσοστό των ψευδώς θετικών δειγμάτων πρέπει να είναι αρκετά χαμηλό ώστε η χρήση του μέσου της διαλογής (screening) να καταστεί χρήσιμη.

the activity concentration index shall be used as a screening tool for identifying materials that may be exempted or subject to restrictions.
Ο δείκτης συγκέντρωσης ραδιενέργειας χρησιμοποιείται ως εργαλείο ελέγχου για τον εντοπισμό υλικών που δύναται να εξαιρούνται ή να υπόκεινται σε περιορισμούς.

as scrat tries to save her, the two hold onto the acorn and the music starts back.
Ενώ ο Σκρατ προσπαθεί να τη σώσει, οι δύο τους κρατάνε το βελανίδι και η μουσική αρχίζει ξανά.

there is, therefore, a need for further standardisation, harmonisation and transparency in screening tools and metrics used by screening agencies.
Συνεπώς είναι αναγκαία η περαιτέρω τυποποίηση, εναρμόνιση και διαφάνεια των εργαλείων ελέγχου και μέτρησης που χρησιμοποιούν τα γραφεία διερεύνησης και ελέγχου.

as mentioned in section 3.1, gambling problem screening tools used in surveys allow for the identificationof individualsthat have severe problems with their gambling behaviour.
Όπως αναφέρθηκε στο τμήμα 3.1, τα μέσα ελέγχου εθισμού σε τυχερά παιχνίδια που χρησιμοποιήθηκαν στην έρευνα επιτρέπουν τον εντοπισμό ατόμων με σοβαρά προβλήματα συμπεριφοράς απέναντι στα τυχερά παιχνίδια.

ideally, the identification of an accurate screening test using a single method or combination of noninvasive methods would decrease the number of unnecessary right heart catheterisations (that is, reduce the false-positive fraction) and increase the true-positive fraction, or the sensitivity, of the screening test for an early and accurate diagnosis of pah in ssc patients. although a number of potential tools are available, further supportive data for their use alone and in combination as part of a screening algorithm are required. detect study the detect (early, simple and reliable detection of pulmonary arterial hypertension in systemic sclerosis) study, which was initiated in 2008, is a prospective, observational, cohort study in two stages consisting of a cross-sectional stage (baseline) and a 3-yr longitudinal follow-up (fig. 3) [56]. the objective of detect is to evaluate a range of accessible, noninvasive screening tools and clinical findings (electrocardiography, echocardiography, serumbiomarkers, pulmonary function testing, 6-min walk test, borg dyspnoea index, medical history, patient demographics and disease characteristics) for their ability to detect pulmonary hypertension in ssc patients, and to identify simple screening methods to support earlier, reliable detection of this complication. with a target recruitment of 500 patients across 91 sites, the study primarily aims to determine the discriminatory and predictive ability of single screening tests for pah in ssc patients compared with right heart catheterisation and single or multiple tests for screening of pah in ssc patients. detect will also allow for the investigation of a range of secondary and exploratory objectives in this large prospective ssc cohort, including the incidence of pah and pulmonary hypertension in ssc over the 3-yr follow-up period, the correlation between change in screening test results and change in measures of clinical status, and the association of potential prognostic or risk factors (e.g. potential biomarkers such as endothelin-1 and anti-nuclear antibodies, etc.) with the development of pah and pulmonary hypertension. although results from this study will undoubtedly be valuable, there are some caveats for their application to the wider ssc population. the study population for detect is restricted to ssc patients with a dl,co ,60% of expected and who are, therefore, at high risk of developing pah. moreover, inclusion criteria state that patients must have ssc disease duration of .3 yrs from onset of first non-raynaud’s symptom. as previously discussed, pulmonary hypertension can be an early complication in a subgroup of patients with ssc [14], which may mean that there are prevalent cases included in the first part of the detect study and these could differ from incident cases identified later. despite this, however, the identification of single or multiple noninvasive screening tests for the early detection of pah in ssc patients by detect would have a significant influence on patient management and would be expected to impact on standards of care in a variety of clinical settings beyond ssc.
google translete